

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97851 A2(51) International Patent Classification⁷: A61K 47/00

FOUNDATION [US/US]; 615 Arapcen Drive, Salt Lake City, UT 84108 (US).

(21) International Application Number: PCT/US01/19625

(22) International Filing Date: 18 June 2001 (18.06.2001)

(72) Inventors; and

(25) Filing Language: English

(75) Inventors/Applicants (for US only): CHOI, Seung-Ho [KR/US]; 3156 Kaibab Way, Salt Lake City, UT 84109 (US). LEE, Jeoung-Soo [KR/US]; 5322 South Cobble Creek Road #16B, Salt Lake City, UT 84117 (US). KEITH, Dennis [US/US]; 64 Lake Street, Arlington, MA 02474 (US).

(26) Publication Language: English

(30) Priority Data:

09/598,089	21 June 2000 (21.06.2000)	US
09/829,405	9 April 2001 (09.04.2001)	US
60/283,976	16 April 2001 (16.04.2001)	US

(74) Agent: FLYNN, Kerry, A.; Cubist Pharmaceuticals, Inc., 24 Emily Street, Cambridge, MA 02139 (US).

(71) Applicants (for all designated States except US): CUBIST PHARMACEUTICALS, INC. [US/US]; 24 Emily Street, Cambridge, MA 02139 (US). INTERNATIONAL HEALTH MANAGEMENT ASSOCIATES, INC. [US/US]; 1675 Winnetka Circle, Rolling Meadows, IL 60008 (US). UNIVERSITY OF UTAH RESEARCH

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,

[Continued on next page]


(54) Title: COMPOSITIONS AND METHODS TO IMPROVE THE ORAL ABSORPTION OF ANTIMICROBIAL AGENTS

NEAD-103

Session 7: OCTX-2 (CTX:Capmul, 1:9)

Session 9: OCTX-2 (No Capmul)

Session 10: CTX (CTX:Capmul, 1:9)



○ Session 7 (Monkey's 1001, 1002)
 ○ Session 9 (Monkey's 1001, 1002, 1003 & 1004)
 △ Session 10 (Monkey's 1001, 1002, 1003 & 1004)

(57) Abstract: The present invention provides compositions and methods for increasing absorption of antibacterial agents, particularly third generation cephalosporin antibacterial agents, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, an antimicrobial agent, and a cationic binding agent contained within the biopolymer such that the binding agent is ionically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent.

WO 01/97851 A2



SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

Published:

— without international search report and to be republished upon receipt of that report

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COMPOSITIONS AND METHODS TO IMPROVE THE ORAL ABSORPTION OF ANTIMICROBIAL AGENTS

FIELD OF THE INVENTION

The present invention is related to compositions and methods for improving the intestinal absorption of antimicrobial agents and their pharmaceutically acceptable salts, esters, ethers or hydrates by combining the selected antimicrobial agent with a cationic binding agent and a biopolymer, and, optionally, an absorption enhancer. Particularly the invention is related to compositions and methods for improving the intestinal absorption of third generation cephalosporin antimicrobial agents, carbapenem and lipopeptide antibacterial agents.

BACKGROUND OF THE INVENTION

The gastrointestinal tract, ("GI") particularly the small intestines, is the primary site for the absorption of nutrients and most bioactive agents. To accommodate the amount of absorption that must take place in the small intestines, the surface area is enlarged due to the presence of villi and microvilli. However, before a bioactive compound is transferred from the intestinal lumen to the blood, the compound may have to withstand degradation or deactivation by the various components of the luminal contents. Moreover, the

compound may be required to pass through several absorption barriers, such as the mucous layer and the intestinal brush-border membrane. Many compounds pass these barriers easily, but there are many nutrients and bioactive agents to
5 which these barriers represent a serious obstruction.

There are many contributing factors which can affect the oral bioavailability of drugs in the gastrointestinal tract. They include for example, characteristics of the GI tract itself, such as the thickness of the epithelium, the surface
10 area, and blood flow, as well as the local physical and chemical environment. Additionally, absorption may be affected by characteristics of the drug substance itself, such as its solubility in water, its chemical stability and molecular weight.

15 Cephalosporin is the general term for a group of antibiotic derivatives of cephalosporin C, which is obtained from the fungus *Cephalosporium Acremonium*. First generation cephalosporins and most second generation cephalosporins are functional in oral dosage forms, though they may be ineffective
20 against many forms of bacteria, such as those found in typical hospital infections. Many third generation cephalosporins, such as ceftiofur, cefixime, cefepime, cefoperazone, cefotaxime,

cefpodoxime, ceftazidime, ceftizoxime and ceftriaxone, due to their broad spectrum of activity, are effective against some bacterial strains that are resistant to many first and second generation cephalosporins. However, since they are generally not orally bioavailable they must be given by injection. There are several contributing factors to the low absorption in the intestines of third generation cephalosporins after oral administration. First, these antibacterial agents are generally highly ionized and hence are very polar and hydrophilic. These properties do not allow them to readily penetrate the hydrophobic intestinal mucosal membrane. Second, due to their reactive properties, these antibacterial agents are generally unstable in an aqueous environment such as in gastric juices and small intestinal fluids.

Therefore, these cephalosporins have been less effective when administered by other than parenteral routes to treat systemic bacterial infections. Frequently these agents must be given more than once daily to achieve the desired level of efficacy. The necessity of obtaining treatment through intravenous (i.v.) or intramuscular (i.m.) injections is inconvenient, as such treatments often require the services of doctors, nurses, or other trained technicians. Additionally,

injections can be painful and cause undue physical and psychological stress to many patients, especially to pediatric patients.

Although ionic surfactants, such as sodium lauryl sulfate, or chelating agents such as EDTA, have been found in some cases to enhance intestinal absorption of large molecules, these substances are known to be harmful to the mucosal membrane.

Other technologies have shown some promise in providing compositions and methods for delivering third generation cephalosporins orally through increased intestinal absorption. In U.S. Patent No. 4,525,339, β -lactam antibacterial agents were shown to penetrate the mucosal membrane of the intestines by co-administering C_2 - C_{12} fatty acid mono-, di-, or triglycerides (i.e. such as Capmuls) as absorption enhancers. In U.S. Patent No. 5,190,748, absorption of antibacterial agents (such as ceftriaxone) through oral and rectal routes was enhanced by utilizing a two-component absorption enhancing system comprising an ether of a C_6 - C_{18} alcohol and a polyoxyethylene glycol together with a second component selected from the group consisting of polyoxyethylene glycol C_6 to C_{18} glyceride esters, C_6 to C_{18} carboxylic acids or salts thereof, and esters of two or more C_6 to C_{18} carboxylic acids, glycerol, and a polyoxyethylene

glycol. Additionally, in U.S. Patent No. 5,318,781, absorption of antibacterial agents (such as ceftriaxone) through oral and rectal routes was enhanced by utilizing a two-component absorption enhancing system comprising Laureth-12 and a second component salt of capric acid and caprylic acids, and a carrier. For optimum absorption, the antimicrobial agent containing the two component enhancer system disclosed therein may include Miglyol-812, which is a capryllic/capric triglyceride. In U.S. Patent No. 4,722,941, the permucosal absorption of various therapeutics, including antibacterial agents, is reported to be enhanced by the use of fatty acids and saturated or unsaturated fatty acid glycerides.

Other disclosures related to improvements in the intestinal delivery of antibiotics include, for example, oral preparations combining a polymer which is soluble only at pH 5.5 or higher and an insoluble polymer targeted for release in the large intestine (European Patent 49,590); and a solid oral dosage form coated with an appropriate amount of anionic polymer WO 83/00435).

Although each of these systems are somewhat effective in delivering antibacterial agents through the mucosal membrane after oral delivery, each has drawbacks that prevent their

widespread use. Some of the compositions and/or methods do not provide significant enough drug delivery such that functional use is practical. Additionally, other compositions and/or methods of mucosal delivery are too costly. As the benefits of
5 third generation cephalosporins and other antibacterial agents have become apparent, it is desirable to provide compositions and methods for administering these antibacterial agents orally, and thus, provide an administration route that is more convenient and cost effective to the patient, and enhances
10 functional concentration of antimicrobial agent that may be absorbed.

Low absorption of oral antimicrobial agents is detrimental for a variety of reasons. Efficacy of the drug may be reduced or eliminated due to the low amounts of drug crossing from the
15 GI tract into the systemic circulation. Safety and tolerability may be compromised since a large amount of the drug ingested may end up in the colon, causing diarrhea, colitis and other gastrointestinal problems. As a result, there may be an increased incidence of drug resistant organisms "selected" in
20 the colon due to the higher levels of drug present.

The present invention addresses the need for orally bioavailable antimicrobial agents by providing compositions and

methods for improving the absorption of antimicrobial agents that overcome the difficulties associated with the methods and compositions known in the art.

SUMMARY OF THE INVENTION

5 The present invention discloses compositions and methods useful for the multitude of therapeutic classes of drugs where lack of transport across the intestinal mucosa limits the systemic uptake of active drug ingredients, or where increased systemic uptake is desired. Such therapeutic classes of drugs
10 include, for example, all antimicrobial agents, including antibacterial agents. The present invention solves these problems by improving the total uptake of active drug into the plasma, allowing for development of new classes of previously unavailable oral antimicrobial agents, allowing for "stepdown
15 therapy" (i.e. transitioning a patient receiving parenteral therapy to oral therapy) within the same antimicrobial class where this option presently doesn't exist, and meeting unmet medical needs for antimicrobial agents with poor safety or tolerability profiles due to issues related to low uptake in the
20 gastrointestinal tract. The present invention additionally may result in improved stability of traditionally unstable compounds by protection of the active ingredient throughout the gut, and

may provide enhanced pharmacokinetic and pharmacodynamic profiles and/or improved post-antibiotic effects.

In one aspect, the present invention provides pharmaceutical compositions for oral delivery of antimicrobial agents comprising (a) a biopolymer, which is preferably swellable and/or mucoadhesive when hydrated; (b) an antimicrobial agent entrained within, or ionically bound, to the biopolymer; and (c) a cationic binding agent ionically bound to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent.

In other embodiments, the present invention provides pharmaceutical compositions for oral delivery of antimicrobial agents comprising (a) a biopolymer, which is preferably swellable and/or mucoadhesive when hydrated; (b) an antimicrobial agent entrained within, or ionically bound, to the biopolymer; (c) a cationic binding agent ionically bound to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent; and (d) an absorption enhancer.

In certain aspects of the invention, the antimicrobial agent is selected from the group consisting of cephalosporins, glycopeptides, penicillins, monobactams, glycycyclines,

macrolides, oxazolidinones, lipopeptides, carbapenems, aminoglycosides, antifungals, β -lactamase inhibitors and combinations thereof.

Biopolymers are known to those skilled in the art, and may vary depending on the desired properties. In various embodiments, the biopolymers used in the claimed invention may include carrageenan, xylan, chitin, chitosan, chondroitin sulfate, sodium alginate, carboxymethylcellulose, pectin, polysaccharides, polypropylene glycols, polyethylene glycols, polyacetates, liposomes, fatty acid complexes, cyclodextrins, cycloamyloses, clathrates, cycloalkyl amyloses, polyxylose, gellan gums and polylactic acids. Preferred biopolymers are carrageenan and pectin.

The invention in additional embodiments includes a cationic binding agent, such as for example, a positively charged metal ion or cationic molecules, including calcium, magnesium, lithium, iron, copper, zinc, aluminum, manganese, chromium, cobalt, nickel, ammonium salts, quaternary ammonium salts and basic amino acids. In preferred embodiments, the cationic binding agent is calcium or zinc. Preferred amino acids include basic amino acids selected from the group consisting of arginine, lysine, histidine, and combinations thereof. Preferred

quaternary ammonium salts are selected from the group consisting of benzalkonium derivatives, cetyl pyridinium derivatives, dodecyl-trimethyl ammonium salt derivatives, tetradecyl-trimethyl ammonium salt derivatives, and cetyl-trimethyl ammonium derivatives. Any combination of the above may be used.

In other embodiments, the invention may include an absorption enhancer, such as some form of lipophilic absorption enhancer, including, for example, lipids, gelucire, capric and/or caprylic acids, oleic acids, palmitic acids, stearic acids, Capmuls, for example, CAPMUL MCM 90 (a mixture of mono- and di-glycerides of saturated C₈-C₁₀ fatty acids with monoglyceride; Abitec, Corp.) or CAPMUL 8210 (similar to MCM, but with about 70% monoglycerides, solid glycerides, sodium lauryl sulfate, fatty acids including mono-, di, or triglycerides, TWEEN 80 (polyoxyethylene sorbitan fatty acid esters), non-ionic surfactants, bile salts, and combinations thereof, as well as any other surfactants known by those skilled in the art. Capmul and gelucire are preferred.

In other embodiments, the antimicrobial agent is a cephalosporin selected from the group consisting of ceftiofur, cefipime, cefixime, cefoperazone, cefotaxime, cefpodoxime,

ceftazidime, ceftizoxime, ceftriaxone, cefpirome, cefclidin, cefmenoxime, ceftazopran, and combinations thereof.

In certain preferred embodiments the antimicrobial agent is a lipopeptide such as daptomycin. Additionally preferred are
5 lipopeptide analogs such as described in U.S.S.N.s 09/738,742, 09/737,908, and 09/739,535, hereby incorporated by reference in their entirety. Other preferred antimicrobial agents are β -lactamase inhibitors.

In other embodiments the antimicrobial agent is an
10 aminoglycoside selected from the group consisting of amikacin, gentamicin, tobramycin, polymyxin-B, streptomycin, kanamycin and combinations thereof.

In yet other embodiments the antimicrobial agent is a glycopeptide selected from the group consisting of vancomycin,
15 dalbavancin, oritavancin and combinations thereof, or a carbapenem selected from the group consisting of meropenem, imipenem, MK0826, R-115,685, J-114,870 and CP5068.

In embodiments where the antimicrobial agent is a monobactam, the agent may be aztreonam or carumonam.

20 In other embodiments, the antimicrobial agent is a penicillin such as piperacillin or amoxicillin, or a

glycopeptide such as vancomycin or daptomycin. In still other embodiments, the preferred cephalosporin is ceftriaxone.

In yet other embodiments the antimicrobial agent is an antifungal agent, for example, selected from the group
5 consisting of amphotericin B, echinocandins, and candidas.

In various embodiments, the cationic binding agent may be ionically bound to the biopolymer forming a cationic binding agent-biopolymer complex and the antimicrobial agent may be entrained within the cationic binding agent-biopolymer complex.

10 In other embodiments, the cationic binding agent may be ionically bound to the antimicrobial agent forming a cationic binding agent-antimicrobial complex and the cationic binding agent-antimicrobial complex is entrained within the biopolymer. Additionally, in some cases, the cationic binding agent may be
15 complexed to the antimicrobial and the cationic binding agent may be further ionically bound to the biopolymer forming an antimicrobial-cationic binding agent-biopolymer bridge.

In preferred embodiments the pharmaceutical compositions of the invention comprise carrageenan, ceftriaxone, and arginine.

20 In other embodiments, the claimed invention encompasses oral formulations for delivery of a pharmaceutical composition having a biopolymer, an antimicrobial agent entrained within or

ionically bound to the biopolymer and a cationic binding agent entrained within or ionically bound to the biopolymer or the antimicrobial. The oral formulations may be tablets, capsules, liquids, suspensions and the like, and may preferably be enterically coated capsules, tablets or particles.

DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphical representation of the results of administering OCTX1 and capmul to monkeys.

Figure 2 is a graphical representation of the results of administering a daptomycin complex according to the invention.

Figure 3 is a graphical comparison of formulations having ceftriaxone + capmul, OCTX2 + an absorption enhancer, and OCTX2 without capmul.

Figure 4 is a graphical representation of the results of administering OCTX1 and capmul to rats.

DETAILED DESCRIPTION OF THE INVENTION

As used herein the following terms shall have the assigned meanings:

It must be noted that, as used in this specification and the appended claims, singular forms of "a," "an," and "the" include plural references unless the content clearly dictates otherwise.

"Absorption Enhancer" shall mean any substance which is effective to increase the absorption of an antimicrobial agent through the mucosa relative to absorption without such agent.

"Biocompatible" shall mean any substance that is not toxic
5 to the animal to be treated.

"Biopolymer" shall mean a biologically compatible polymer which can be naturally occurring or synthetic. Examples include carrageenan, xylan, chitin, chitosan, carboxymethylcellulose, pectin, polysaccharides, polypropylene glycols, polyethylene
10 glycols, polyacetates, polylactic acids, liposomes, gellan gums, fatty acid complexes, cyclodextrins, cycloamyloses, clathrates, cycloalkyl amyloses and polyxylose.

"Capmul" as used herein shall mean a mono, di- or triglyceride of a C₈-C₁₈ fatty acid or a mixture of such
15 glycerides.

"Poorly absorbable antimicrobial" shall mean any antimicrobial agent that exhibits low bioavailability in oral or other non-parenteral dosage form, typically due to relatively high hydrophilicity and/or ionization properties of the
20 antimicrobial agent. The antimicrobial agent can be positively charged, negatively charged, zwitterionic or amphiphilic.

"Oral absorption" is used to describe the manner in which the compositions of the present invention are delivered to the subject and the active ingredients absorbed into the blood.

Typically, the composition is administered orally and the antimicrobial agent of the composition then crosses a mucosal membrane of the gastro-intestinal tract, preferably in the intestines. However, other methods of contacting the compositions of the present invention with the mucosal membrane of the gastro-intestinal tract may be used.

"Metal ion" or "metal cation" shall mean any positively charged metal ion that is functional for use with the present invention. Essentially, the metal cation binds to the antimicrobial agent and/or the biopolymer in accordance with the present invention. The metal cation may be complexed, chelated, or ionically bound to the antimicrobial agent. Exemplary metal cations include, but are not limited to calcium, potassium, magnesium, iron, copper, zinc, aluminum, manganese, chromium, cobalt, nickel, sodium, and combinations thereof.

"Cationic molecule" shall mean any molecule with one or more positively charged moieties that act to ionically bind to the antimicrobial agent and/or the biopolymer. Negatively charged moieties can also be present, though this is not

required. Exemplary cationic molecules include cationic polymers, basic amino acids, quaternary ammonium salts, ammonium salts and combinations thereof.

"Cationic binding agent" is intended to include both metal
5 cations and cationic molecules.

"Swellable" shall mean that the biopolymers and/or compositions of the present invention have the ability to swell or enlarge, such as when hydrated.

"Mucoadhesive" shall mean any biopolymer that is capable of
10 adhering to a mucosal membrane, particularly when hydrated.

"OCTX" as used herein refers to a complex comprising ceftriaxone, a biopolymer and a cationic binding agent.

The claimed invention provides methods and compositions for treating infections in humans and other animals (collectively
15 referred to as "animals" herein) by providing for the increased absorption of oral antimicrobial agents. In general, the compositions of the invention comprise a pharmaceutical composition for oral administration to a human or other animal comprising an antimicrobial agent, a biopolymer, and a cationic
20 binding agent which is ionically bound to at least one of the biopolymer or the antimicrobial agent. The absorption of antimicrobial agents is significantly enhanced by the

compositions and methods of the present invention. Although not limited to any particular mechanism of action, the claimed invention may enhance the stability of the antimicrobial agent, and partially neutralize the ionic charge (especially relevant
5 for the readily ionizable third generation cephalosporins) thereby facilitating mucosal absorption through the intestinal wall. The intestinal absorption of these antibacterial agents may be enhanced for any oral formulation, including for example, solid, liquid, emulsion and suspension dosage forms.

10 In certain embodiments the claimed invention provides a pharmaceutical composition for oral delivery of an antimicrobial agent comprising (a) a biopolymer (b) an antimicrobial agent entrained within, or ionically bound to, the biopolymer; and (c) a cationic binding agent ionically bound to at least one of the
15 biopolymer or the antimicrobial agent. Such compositions can be prepared for oral dosage in, for example, solid, liquid, emulsion or suspension forms. Additionally, the present invention provides methods for the delivery of therapeutic or prophylactic antimicrobial agents to the bloodstream of an
20 animal comprising the steps of (a) orally administering to an animal a pharmaceutical composition comprising a biopolymer, an effective amount of a antimicrobial agent entrained within, or

ionically bound, to the biopolymer, and a cationic binding agent ionically bound to at least one of the biopolymer or the antimicrobial agent; (b) causing the biopolymer to swell and adhere to a mucosal membrane lining of an intestinal wall of the animal such that the antimicrobial agent, and in certain embodiments, the cationic binding agent, in the composition will be delivered to the mucosal membrane lining, cross the intestinal wall and enter the bloodstream. In preferred methods of delivering the pharmaceutical composition to be administered additionally comprises an absorption enhancer.

In yet other embodiments the claimed invention encompasses methods of treating an animal by administering to an animal in need thereof a (1) pharmaceutical composition having an antimicrobial agent, a cationic binding agent and a biopolymer, and (2) an absorption enhancer.

ANTIMICROBIAL AGENTS:

One skilled in the art can readily determine the desired antimicrobial agent to be used in the claimed compositions and methods, as well as the dosage to be administered. This determination may be based upon a multitude of factors, including, but not limited to the infection to be treated, the pharmacokinetics and pharmacodynamics of the antimicrobial

agent, the identity and susceptibility of the infecting microbe, the severity of the infection and the age and medical history of the animal to be treated.

In preferred embodiments, the antimicrobials of the
5 invention are selected from the group consisting of cephalosporins, aminoglycosides, carbapenems, β -lactamase inhibitors, antifungals, penicillins, lipopeptides, glycopeptides, monobactams, and oxazolidinones.

Preferred antimicrobials of the invention include, but are
10 not limited to cephalosporins, such as, for example, ceftiofur, cefipime, cefixime, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftizoxime, ceftriaxone, cefmenoxime, ceftazopran, cefpirome, and cefclidin. Additionally, MRSA-active cephalosporins which are in development stages such as RO 65-
15 5788 (U.S. Patent No. 6,232,306, hereby incorporated by reference in its entirety), RWJ-54428 (U.S. Patent No. 6,025,352, hereby incorporated by reference in its entirety), RWJ-333441 (Curr. Opin. Invest. Drugs (2001); 2(2) 209-211, hereby incorporated by reference) are appropriate for use in the
20 invention. Additionally, cephalosporins such as described in U.S. Patent No. 6,093,813 (hereby incorporated by reference) are useful. The most preferred cephalosporin is ceftriaxone, such

as described in U.S.S.N 09/598,089 (to be issued as U.S. Patent No. 6,248,360), and U.S.S.N 09/829,405.

In other embodiments, the antimicrobials of the invention can be selected from aminoglycosides, such as, for example
5 amikacin, gentamicin, tobramycin, polymixin-B, streptomycin, and kanamycin. The agent may in some embodiments be a glycycline.

In other preferred embodiments, the antimicrobials to be used in the claimed invention are carbapenems, such as for example, one or more selected from the group consisting of
10 meropenem, imipenem, MK0826 (Invanz, WO 99/45010, hereby incorporated by reference), R-115,685 (Sankyo, WO 01/02401 hereby incorporated by reference), J-114,870 (Banyu, WO 99/31106 hereby incorporated by reference) and CP-5068 (Meiji, see R&D Focus, Feb. 19, 2001; IMS World Publications).

15 Additionally, the compounds of the invention may be a β -lactamase inhibitor such as tazobactam, oxapenem, clavulanic acid, sublactam, or, for example, Zosyn[®], which is a combination of tazobactam and piperacillin marketed by Wyeth-Ayerst.


Lipopeptides such as daptomycin, and the analogs disclosed
20 in U.S.S.N.s 09/738,742, 09/737,908, and 09/739,535, hereby incorporated by reference in their entirety.

Additional antimicrobials which are preferred include glycopeptides such as vancomycin, dalbavancin and oritavancin, monobactams such as aztreonam or carumonam.

In some embodiments the antimicrobial agent of the invention comprises an anti-fungal agent, such as for example, amphotericin B, echinocandins and candidas.


In other embodiments, penicillins are preferred, such as, for example, piperacillin and amoxicillin.

Most preferred are ceftriaxone (Formula 1) and daptomycin (Formula 2). Ceftriaxone is a poorly absorbable antibiotic, and thus, prior to the claimed invention, was not amenable to oral administration. The ceftriaxone molecule has several inherent characteristics which may contribute to its poor oral bioavailability, including for example, its polarity and hydrophobicity, and the fact that it is unstable in the presence of acid and peptidases by virtue of the presence of peptide bonds. The ceftriaxone salt of formula 1 is most preferred.



Formula 1.

Daptomycin (shown in formula 2) is a lipopeptide
5 described in detail in U.S. Patent 5,912,226 (and referred to
therein as LY 146032), herein incorporated by reference in its
entirety. Additionally preferred are lipopeptide analogs such as
described in Pending U.S. serial numbers 09/738,742, 09/737,908,
and 09/739,535, hereby incorporated by reference in their
10 entirety.



Formula 2

5 BIOPOLYMERS:

The claimed invention may comprise any biopolymer that is not toxic to the animal to be treated, and provides for the desired characteristics of the pharmaceutical composition.

However, mucoadhesive and/or swellable biopolymers are the most preferred. Exemplary biopolymers include, but are not limited to carrageenans, pectins, chondroitin sulfate, sodium alginate, and/or polymethacrylic acid, xylan, hyaluronic acid, chitin, chitosan, chondroitin sulfate, sodium alginate, carboxymethylcellulose, pectin, polysaccharides, polypropylene glycols, polyethylene glycols, polyacetates, liposomes, fatty

acid complexes, cyclodextrins, cycloamyloses, clathrates, cycloalkyl amyloses, polyxylose and polylactic acids.

Carrageenan and pectin are most preferred.

Carrageenan is the general term used to describe
5 hydrophilic polysaccharides extracted from a number of closely related species of red seaweeds that are highly sulfated, linear molecules having a galactose backbone. There are three different types of carrageenan, Kappa, Lambda and Iota, which are differentiated by the amount of 3,6-anhydrogalactose
10 residues and number and position of the sulfate groups. For example, the following carrageenans can be obtained from FMC Biopolymer: Gelcarin® GP 379 (Iota) and Gelcarin® GP 911 (Kappa). The carrageenan may have a calcium content of about 3.6% by weight.

15 The preferred carrageenan for certain compositions of the invention is a carrageenan having a low calcium content, i.e a calcium content of from about 0 to about 3%, more preferably about 0-2%, and most preferably about 0.1-1% calcium by weight. The most preferred carrageenan has a sodium content of about 0.4%
20 or less, such as, for example, Viscarin® XP (FMC Biopolymer). In certain compositions, processing with other carrageenans resulted in undesired precipitation of the active antimicrobial

agent. Most preferred compositions comprise ceftriaxone as the antimicrobial agent, low calcium carrageenan, calcium, and Capmul. OCTX2 as defined in Example 2 is most preferred.

CATIONIC BINDING AGENTS:

5 Any cationic binding agent can be used in the claimed invention, and preferred cationic binding agents include for example, any positively charged metal ion, or any charged cationic molecules, such as, for example, calcium, potassium, magnesium, lithium, iron, copper, zinc, sodium, aluminum, manganese, chromium, cobalt, nickel, ammonium salts, quaternary ammonium salts such as benzalkonium derivatives, cetyl pyridinium derivatives, dodecyl-trimethyl ammonium salt derivatives, tetradecyl-trimethyl ammonium salt derivatives and cetyl-trimethyl ammonium salt derivatives. Additionally, basic amino acids such as arginine, lysine and histidine are preferred cationic binding agents.

Preferred metal cations include, for example, calcium, potassium, magnesium, iron, copper, zinc, aluminum, manganese, chromium, cobalt, nickel, and/or sodium. These cations are preferred because each of these metal cations are biocompatible.

However, cations such as zinc, and particularly, calcium are most preferred.

The metal cation can be arranged in relation to the biopolymer and the poorly absorbable antimicrobial agent in one of three preferred manners. First, the metal cation can be bound to the biopolymer forming a cation-biopolymer combination
5 such that the antimicrobial agent is entrained within the cationic-biopolymer ionic combination. Second, the metal cation can be complexed to the antimicrobial agent and the cation-antimicrobial agent complex can then be entrained within the biopolymer. Third, the metal cation can be complexed to the
10 antimicrobial agent and further bound to the biopolymer forming an antimicrobial agent-cation-biopolymer bridge. When using the metal cation as the binding agent, the compositions of the present invention may be prepared in both solid form (e.g., tablets, capsules, etc.), liquids, emulsions and suspension
15 form. The formulations in other embodiments may comprise granules which are compacted into tablet form, or placed in capsules.

If a cationic molecule is used as the binding agent (rather than the metal cation), then there are three preferred molecular
20 types that may be used. First, cationic polymers including, but not limited to, poly(allylamine, poly-(l-lysine), poly(arginine) and dodecyltrimethylammonium bromide. Also

polyethylenimines (primary, secondary, and tertiary) may be used. Further, the cationic molecule may be a quaternary ammonium salt including, but not limited to, benzalkonium derivatives, cetylpyridinium derivatives such as chlorides or bromides, dodecyl-trimethyl ammonium salt derivatives, tetradecyl-trimethyl ammonium salt derivatives, and/or cetyl-trimethyl ammonium salt derivatives.

LIPIDS

Preferred compositions comprise an absorption enhancer, such as a lipid or, alternatively, comprise a polymer or antimicrobial agent having lipid-like properties. For example, the compositions described in Example 7 contain cetylpyridinium, which, in addition to providing a positive charge, may contribute lipid-like properties to the composition, and therefore the desired effect can be seen in the absence of adding a lipid to the composition.

Frequently used absorption enhancers include for example, lipids, gelucire, capric and caprylic acids, oleic acids, palmitic acids, stearic acids, Capmuls, for example, CAPMUL MCM (a mixture of mono- and di-glycerides of saturated C₈-C₁₀ fatty acids with monoglyceride; Abitec, Corp.) or CAPMUL 8210 (similar to MCM, but with about 70% monoglycerides). Capmul is

preferred, and can be present in the composition in any desired ratio, preferably from 12:1 to 1:1 capmul:OCTX by weight.

Alternatively, any known absorption enhancers may be used, including any mixtures of the above. Capmul and gelucire are

5 preferred.

With each of these compositions and methods, the antimicrobial agent and binding agent can be present within a specific preferred molar ratio, though these ratios are not intended to cover all effective compositions. For example, if a
10 metal cation is used as the binding agent, then the antimicrobial agent to metal cation molar ratio can be from about 30:1 to 1:5, preferably about 20:1 to 5:1, and most preferably, about 20:1 by weight. Additionally, the antimicrobial agent to biopolymer molar ratio can be from about
15 5:1 to 1:5, preferably about 2:1. Alternatively, if a cationic molecule is used as the binding agent, then the antimicrobial agent to cationic molecule molar ratio can be from about 1:4 to 1:1, preferably from about 1:2 to 1:1, e.g., 1:2 for antimicrobial agent:amino acid embodiments and 1:1 for
20 antimicrobial agent:cetyl pyridinium embodiments. Additionally, in this embodiment, the antimicrobial agent to biopolymer molar ratio can be from about 5:1 to 1:5, preferably about 2:1.

FORMULATIONS

The compositions of the invention are formulated for oral administration to an animal, and preferably may be in solid formulations such as tablets and capsules. Sustained release or enterically coated preparations may also be devised. For pediatric and geriatric applications, emulsions, suspensions, syrups and chewable tablets may be especially suitable. For oral administration, the claimed pharmaceutical compositions are in the form of, for example, a tablet, capsule, suspension or liquid. The composition is preferably in the form of a dosage unit containing a therapeutically-effective amount of the antimicrobial agent. The tablets and capsules of the invention can contain, in addition to the active ingredients, conventional carriers such as binding agents, for example, acacia gum, gelatin, polyvinylpyrrolidone, sorbitol, or tragacanth; fillers, for example, calcium phosphate, glycine, lactose, maize-starch, sorbitol, or sucrose; lubricants for example, magnesium stearate, polyethylene glycol, silica or talc; disintegrants, for example, potato starch, flavoring or coloring agents, or acceptable wetting agents. Oral liquid preparations generally may be in the form of aqueous or oily solutions, suspensions, emulsions, syrups or elixirs, and may contain conventional

additives such as suspending agents, emulsifying agents, non-aqueous agents, preservatives, coloring agents and flavoring agents. In either case, the composition is designed such that the antimicrobial agent may be transmucosally delivered into the
5 bloodstream, preferably through the walls of the small intestines.

In certain embodiments the claimed compositions may comprise more than one antimicrobial agent. This is especially useful when treating infections resulting from more than one
10 infecting microbial organism.

Factors to be considered in choosing the appropriate antimicrobial agent to be used in the invention include, for example, the identity of the infecting organism, the antimicrobial susceptibility (or potential susceptibility) of
15 the infecting organism, and a variety of factors related to the animal to be treated, including, for example, patient history, age, site and severity of infection, etc. Additional considerations include the pharmacokinetic and pharmacodynamic properties of the antimicrobial agent. Oral compositions may
20 take such forms as tablets, capsules, oral suspensions and oral solutions. The oral compositions may utilize carriers such as conventional formulating agents, and may include sustained release properties as well as rapid delivery forms.

Capsules are preferred. Any capsule material known in the art can be used depending upon the desired dissolution characteristics of the pharmaceutical compositions. For example, capsules may comprise hydroxypropylmethylcellulose, a
5 mixture of polyethylene glycol with hydroxypropylmethylcellulose, gelatin or agar.

Preferably, the compositions of the invention are formulated with enteric coatings in order to prevent the degradation of the antimicrobial agent by the acidity of the
10 gastric fluid and optimize delivery of the active agent to the desired location in the intestine. Capsules can be coated with selected materials depending upon the desired capsule characteristics, and may include, for example, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl
15 acetate phthalate, shellac, methacrylic acid and esters thereof, zein, or other materials known in the art. The enteric coating materials may be applied with or without plasticizers, such as acetylated glycerides, triethyl citrate, propylene glycol or diethylphthalates. Preferred coating materials are those which
20 dissolve at a pH of 5 or above. The coatings therefore only begin to dissolve when they have left the stomach and entered the small intestine. A thick layer of coating is provided which will dissolve in about fifteen minutes thereby allowing the

capsule underneath to breakup only when it has reached the duodenum. Such a coating can be made from a variety of polymers such as cellulose acetate trimellitate (CAT), hydroxypropylmethyl cellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP) and shellac as described by Healy in his article "Enteric Coatings and Delayed Release" Chapter 7 in Drug Delivery to the Gastrointestinal Tract, editors Hardy et al., Ellis Horwood, Chichester, 1989. For coatings of cellulose esters, a thickness of 200-250 μm would be suitable.

Especially preferred materials are methylmethacrylates or copolymers of methacrylic acid and methylmethacrylate. Such materials are available as EUDRAGITTM polymers (Rohm Pharma, Darmstadt, Germany). Eudragits are copolymers of methacrylic acid and methylmethacrylate. Preferred compositions are based on EUDRAGIT L 30 D-55, EUDRAGIT L1W-55, EUDRAGITTM L100 and Eudragit S100. EUDRAGIT L30-D55 AND L1W-55 dissolve at $\text{pH} \geq 5.5$. EUDRAGITTM L100 dissolves at $\text{pH} 6$ and upwards and comprises 48.3% methacrylic acid units per g dry substance; EUDRAGITTM S100 dissolves at $\text{pH} 7$ and upwards and comprises 29.2% methacrylic acid units per g dry substance. Preferred coating compositions are based on EUDRAGITTM L100 and EUDRAGITTM S100 in the range 100 parts L100:0 parts S100 to 20 parts L100:80 parts S100. The most

preferable range is 70 parts L100:30 parts S100 to 80 parts L100:20 parts S100. As the pH at which the coating begins to dissolve increases, the thickness necessary to achieve colon specific delivery decreases. For formulations where the ratio of EUDRAGIT™ L100:S100 is high, a coat thickness of the order 150-200 µm is preferable. This is equivalent to 70-110 mg of coating for a size 0 capsule. For coatings where the ratio EUDRAGIT™ L100:S100 is low, a coat thickness of the order 80-120 µm is preferable, equivalent to 30 to 60 mg coating for a size 0 capsule.

10 Most preferred is EUDRAGIT L30-D55, for delivery in the duodenum (i.e. ≥ 5.5 pH and less than 6.8.)

The dosage to be administered depends to a large extent upon the condition and size of the subject being treated, the route and frequency of administration, the sensitivity of the pathogen to the particular compound selected, the virulence of the infection and other factors. Such matters, however, are left to the routine discretion of the physician according to principles of treatment well known in the antibacterial arts. Another factor influencing the precise dosage regimen, apart from the nature of the infection and peculiar identity of the individual being treated, is the molecular weight of the compound. Preferred dosages for example, for the administration of ceftriaxone compositions may be from about 0.25 to about 8

grams per day, more preferably about 2 to about 4 grams per day. The dosage intervals can be determined by one skilled in the art, and may for example, be every 6 to every 24 hours. Preferred dosages for the administration of daptomycin

5 compositions according to the invention, for example, are in the range of from about 2 to about 15 mg/kg, more preferably about 8-10 mg/kg day.

The compositions of the invention are useful in methods of treating subjects having an infection. The term "treating"
10 is used to denote both the prevention of an infection and the control of an established infection once the host animal has become infected. The methods of the invention comprise administering to a human or other animal a therapeutically or prophylactically effective amount of the antimicrobial agent.
15 "Therapeutically effective amount" means an amount of antimicrobial agent sufficient to prevent the onset, alleviate the symptoms, or stop the progression of a microbial infection.

The compositions of the invention can be administered as a single daily dose or in multiple doses per day. The treatment
20 regime may require administration over extended periods of time, e.g. for several days or for several weeks. The amount per administered dose or the total amount administered will depend on such factors as the nature and severity of the infection, the

age and general health of the patient, the tolerance of the patient to the antimicrobial agent and the microorganism or microorganisms involved in the infection. For example, in certain embodiments, the compositions of the invention can be
5 used to treat respiratory tract infections, skin and soft tissue infections, urinary tract infections, sinusitis, sexually transmitted diseases, endocarditis, bacteremia, osteomyelitis, septicemia and lyme disease.

In certain embodiments, the claimed invention encompasses a
10 method of treating an animal comprising the steps of (1) administering to the animal a pharmaceutical composition comprising a biopolymer, an antimicrobial agent, and a cationic binding agent, and (2) an absorption enhancer. In other embodiments, the claimed invention encompasses methods of
15 treating an animal comprising administering to the animal a pharmaceutical composition comprising a biopolymer, an antimicrobial agent, a cationic binding agent and an absorption enhancer.

The following examples are not intended to be limiting and
20 further exemplify various embodiments of the claimed invention.

Examples:1. PREPARATION OF OCTX1

About 400 mg of carrageenan was added to 80 ml of an aqueous solution at approximately 55°C. The solution was then
5 mixed by magnetic stirrer at room temperature until the carrageenan was essentially fully swollen. Next, an aqueous solution containing Ca^{2+} ions was prepared by dissolving 44.5 mg (0.33 mole) of calcium chloride in 10 ml of water. An aqueous solution of CTX was prepared by dissolving 1.0 g of ceftriaxone
10 sodium in 10 ml of water. The entire volume of CTX and CaCl_2 solutions were simultaneously added dropwise to the CG solution. The dispersion was centrifuged and the supernatant removed for subsequent lyophilization to dryness. The resulting composition comprises
15 Carrageenan 0.4g (27.7%), Ceftriaxone 1g (69.2%), Calcium Chloride 0.0445 g (3.1%), and can be milled to yield a fine powder.

2. PREPARATION OF OCTX2

An aqueous solution of calcium chloride is prepared by
20 dissolving approximately 0.0114 g of CaCl_2 in 80 ml of an aqueous solution. About 400 mg of low calcium carrageenan ($<0.4\% \text{Ca}^{++}$) is hydrated in the CaCl_2 solution. Then 1.0 g of ceftriaxone is dissolved in 20 ml of water and added to the solution at room

temperature. The resulting composition comprises 69.2 % ceftriaxone, 28.4% low calcium carrageenan and 0.7% CaCl_2 .

3. PREPARATION OF A CTX-ZN-CG COMPLEX

About 400 mg of carrageenan was added to 80 ml of an aqueous solution containing 1.0 g (1.67 mole) of ceftriaxone. The solution was then mixed by magnetic stirrer at room temperature until the carrageenan was essentially fully swollen, forming a ceftriaxone-carrageenan hydrogel. Next, an aqueous solution containing zinc ions was prepared by dissolving 45 mg (0.33 mole) of zinc chloride in 20 ml of water. The entire aqueous solution was then dropped into the ceftriaxone-carrageenan hydrogel or suspension. The complex was then stirred by a magnetic stirrer at room temperature for 2 hours. This resulted in the formation of a ceftriaxone-zinc-carrageenan gel complex. The ceftriaxone-zinc-carrageenan gel was then freeze-dried while in the swollen state. About 1.4 grams of a ceftriaxone-zinc-carrageenan complex was obtained.

About 40 mg CTX eq./kg of the ceftriaxone-zinc-carrageenan complex was suspended in water and i.d. administered with 0.2 ml of capmul per rat (wgt about 300 g) to four rats. At specific time intervals, 0.6 ml of blood was taken from each rat and centrifuged. About 0.2 ml of the blood plasma was then analyzed for CTX by HPLC. The results are represented in Table 1 below:

TABLE 1

Time After i.d. Dosage (minutes)	Average Plasma Concentration of CTX ($\mu\text{g/ml}$)
30	17
60	16
90	17
120	13
180	14
240	8

4. PREPARATION OF A CTX-ARG-CG COMPLEX

5 About 582 mg (3.34 mole) of arginine was dissolved in 50 ml
of distilled water. Additionally, about 1.0 grams (1.67 mole)
of ceftriaxone was dissolved in 50 ml of a separate volume of
distilled water. The solution containing arginine was adjusted
with 1N-HCl until the pH reached 6.0. The ceftriaxone solution
10 was then added to the arginine solution and mixed by a magnetic
stirrer at room temperature for 1 hour forming a ceftriaxone-
arginine solution. To the ceftriaxone-arginine solution was
added about 400 mg of carrageenan and the solution was mixed by
magnetic stirrer at room temperature for 2 hours. A

ceftriaxone-arginine-carrageenan complex was formed which was freeze-dried while in the swollen state, yielding about 1.84 g of the freeze dried complex.

About 40 mg CTX eq./kg of the ceftriaxone-arginine-carrageenan complex described above was suspended in water and i.d. administered with 0.2 ml of capmul to four rats. At specific time intervals, 0.6 ml of blood was taken from each rat and centrifuged. About 0.2 ml of the blood plasma was then analyzed for CTX by HPLC. The results are represented in Table 2 below:

TABLE 2

Time After i.d. Dosage (minutes)	Average Plasma Concentration of CTX ($\mu\text{g/ml}$)
30	57
60	39
90	26
120	20
180	13
240	9

About 610 mg (3.34 mole) of lysine was dissolved in 50 ml of distilled water. Additionally, 1.0 gram (1.67 mole) of

ceftriaxone was dissolved in 50 ml of a separate volume of distilled water. The solution containing arginine was adjusted with 1N-HCl until the solution reached pH 6.0. The ceftriaxone solution was then added to the lysine solution and stirred by a magnetic stirrer at room temperature for 1 hour forming a ceftriaxone-lysine solution. To the ceftriaxone-lysine solution was added about 400 mg of carrageenan and the solution was stirred by magnetic stirrer at room temperature for 2 hours. A ceftriaxone-lysine-carrageenan hydrogel was formed. The hydrogel was then freeze-dried while in the swollen state, yielding about 1.92 g of the freeze-dried complex.

About 40 mg CTX eq./kg of the ceftriaxone-lysine-carrageenan complex described was suspended in water and i.d. administered with 0.2 ml of capmul to four rats. At specific time intervals, 0.6 ml of blood was taken from each rat and centrifuged. About 0.2 ml of the blood plasma was then analyzed for CTX by HPLC. The results are represented in Table 3 below:

TABLE 3

Time After i.d. Dosage (minutes)	Average Plasma Concentration of CTX ($\mu\text{g/ml}$)
30	14
60	6
90	5
120	4
180	3
240	2

6. PREPARATION OF CTX-HIS-CG COMPLEX

About 518.4 mg (3.34 mole) of histidine was dissolved in 50
5 ml of distilled water. Additionally, about 1.0 grams (1.67
mole) of ceftriaxone was dissolved in 50 ml of a separate volume
of distilled water. The solution containing histidine was
adjusted with 1N-HCl until the solution reached pH 5.5. Next,
the ceftriaxone solution was added to the histidine solution and
10 stirred by a magnetic stirrer at room temperature for 1 hour
forming a ceftriaxone-histidine complex solution. About 400 mg
of carrageenan was added to ceftriaxone-histidine solution and
stirred by magnetic stirrer at room temperature for 2 hours.
After the stirring was complete, a white suspension was formed

in the hydrogel. The ceftriaxone-histidine-carrageenan hydrogel in a swollen state was rapidly freeze-dried using a dry-ice-acetone mixture. About 1.75 g of product was produced.

7. PREPARATION OF A CTX-CP-CG COMPLEX

5 About 210 mg (0.62 mole) of particulate cetylpyridinium chloride was dissolved in 50 ml of distilled water. Additionally, about 378 mg (0.62 mole) of ceftriaxone was dissolved in 50 ml of a separate volume of distilled water. Next, the ceftriaxone solution was added to the cetylpyridinium
10 chloride solution and stirred by a magnetic stirrer at room temperature for 1 hour forming a ceftriaxone-cetylpyridinium chloride solution. About 400 mg of carrageenan was added to the ceftriaxone-cetylpyridinium chloride solution and the solution was stirred by magnetic stirrer at room temperature for 2 hours.
15 A ceftriaxone-cetylpyridinium chloride-carrageenan hydrogel complex was formed. The complex was then freeze-dried, yielding about 0.86 g of the freeze-dried complex.

 About 40 mg CTX eq./kg of the ceftriaxone-cetylpyridinium chloride-carrageenan complex described above was suspended in
20 water and i.d. administered without capmul to four rats. At specific time intervals, 0.6 ml of blood was taken from each rat and centrifuged. About 0.2 ml of the blood plasma was then analyzed for CTX by HPLC. The results are represented in Table

4 below:

TABLE 4

Time After i.d. Dosage (minutes)	Average Plasma Concentration of CTX ($\mu\text{g/ml}$)
30	28
60	30
90	29
120	27
180	25
240	21

8. PREPARATION OF CTX-Ca-CG

5 400 mgs of carrageenan (CG) was added into 80 ml distilled
water at 50°C and stirred until fully hydrated. 10 ml of
ceftriaxone solution and 10 ml of various concentrations of CaCl_2
solution were added dropwise into the CG solution simultaneously
and stirred for additional 30 minutes at 50°C. The formed CTX-
10 Ca-CG was centrifuged at 5,000 rpm for 10 min and the
supernatant was freeze-dried. The amount of CTX in the
formulation was analyzed by UV-VIS spectroscopy (λ_{max} -272 nm).

9. PREPARATION OF CTX-Ca-PT

400 mgs of pectin (PT) was added into 80 ml. distilled water at 50°C and stirred until fully swollen. 10 ml of ceftriaxone solution and 10 ml of various concentrations of CaCl₂ solution were added dropwise into the PT solution simultaneously and stirred for an additional 30 minutes at 50°C. The formed CTX-Ca-PT was freeze-dried. The amount of CTX in the formulation was analyzed by UV-VIS spectroscopy (λ_{max} -272 nm).

INTRAVENOUS ADMINISTRATION TO RATS

Male Srague Dawley rats weighing 250-300 g with free access to water were fasted for about 18 hr. prior to the experiment. These rats were anesthetized with 5.0 mg/100 g of pentobarbital by intraperitoneal injection. Ceftriaxone was dissolved in distilled water to achieve a final concentration of 20 mg/kg and injected into a jugular vein. Blood samples were collected through the jugular vein catheter at predetermined time intervals.

INTRADUODENAL ADMINISTRATION TO RATS

To determine absorption from the intestine, male Sprague Dawley rats weighing 250- 300 g with free access to water were fasted for about 18 hours prior to the experiment. These rats were anesthetized and maintained with Ketamine/Xlazine ((60

mg/kg)/(80 mg/kg)) by intraperitoneal injection. The small intestine was exposed by a midline abdominal incision. A small incision was made in the stomach to insert a polyethylene tube (i.d. 0.76mm, o.d. 1.22mm, Clay Adams) toward the duodenum, which was closed at the exposed end by a stopcock to prevent drainage of drug solution from the duodenum. Ceftriaxone and oral formulations of CTX were dissolved in distilled water to achieve a final concentration of 40 mg CTX eq./kg and injected into the duodenum using the tube. Then 0.2 ml mono- and diglyceride mixture (Capmul) was coadministered into the duodenum using the intraduodenal tube. Blood samples were taken with a heparinized syringe through the jugular vein catheter at predetermined intervals.

ANALYSIS OF CEFTRIAXONE

The concentration of ceftriaxone in the plasma was determined by HPLC. Blood samples were centrifuged for 5 min at 5,000 rpm and 0.2 ml of plasma was taken into the microtube. 0.2 ml plasma was diluted by 0.2 ml of distilled water, and then 0.8 ml of acetonitrile was added for protein removal. The resulting suspensions were centrifuged for 10 min at 12,000 rpm and 50 μ l of the clear supernatant was used for HPLC analysis. The i.v. and i.d. data were analyzed by Pharsight Winnonlin ver 3.0 to obtain C_{max} , T_{max} , $AUC_{0-4 \text{ hours}}$, and AUC_{inf} from plasma

concentration-time curve. Percent bioavailability was calculated as follows: % BA = (AUC i.d. / AUC i.v.) x (Dose i.v. / Dose i.d.) x 100

Table 5: Pharmacokinetic Data of Ceftriaxone (CTX) after i.d. administration of various CTX-CA-CG in rats. All but i.v. received 0.2 ml. capmul chase.

sample	Cmax (µg/ml)	Tmax (hr)	AUC _{0-4hr} (µg·hr/ml)	AUC _∞ (µg·hr/ml)	BA _{0-4hr} (%)	BA _∞ (%)
i.v. CTX	-----	-----	1.68.2±29.4	188.0±6.4	-----	-----
i.d. CTX	17.2	1.0	31.7±12.4	52.3±32.4	9.4	13.9
CTX1-CG4	15.32	0.67	33.7±19.5	47.4±25.8	10.0	12.68
CTX1-Ca0.1 - CG4	36.96	1.0	82.8±36.5	106.0±44.4	24.6	28.2
Ca 0.2-CG4	69.1	0.5	124.3 ± 0.5	136.0±0.1	24.6	28.2
CTX1-Ca0.5-CG4	14.0	0.5	20.6±4.5	22.7 ± 5.1	6.1	6.8
Ca1-CG4	n.a	n.a	n.a	n.a	n.a	n.a.

i.d. CTX: control; n.a.: no absorption

i.v. dose: 20mg CTX/kg, i.d. dose: 40 mg CTX eq/kg.

ratios are relative amounts as follows: CTX g-Ca M-CG mg

Table 6. Pharmacokinetic data of Ceftriaxone after i.d. administration of various CTX-Ca-Pectin in rats. All but i.v. received 0.2 ml capmul chase

5

sample	Cmax ($\mu\text{g/ml}$)	Tmax (hr)	AUC _{0-4hr} ($\mu\text{ghr/ml}$)	AUC ₀₀ ($\mu\text{ghr/ml}$)	BA _{0-4hr} (%)	BA ₀₀ (%)
i.v.						
CTX	-----	-----	1.68.2 \pm 29.4	188.0 \pm 6.4	-----	-----
i.d.						
CTX	17.2	1.0	31.7 \pm 12.4	52.3 \pm 32.4	9.4	13.9
CTX1-PT4	57.3	0.5	105.5 \pm 32.6	128.8 \pm 29.6	29.9	38.3
CTX1- Ca0.2- PT4	67.43	0.678	133.6 \pm 48.1	224.0 \pm 131.7	40.6	66.6
PT8	27.51	0.5	46.5 \pm 22.2	54.6 \pm 29.3	13.8	16.2
CTX1- Ca0.4- PT4	54.8	0.5	81.6 \pm 22.1	94.2 \pm 24.0	24.2	28.0

i.d. CTX: control; n.a.: no absorption

i.v. dose: 20mg CTX/kg, i.d. dose: 40 mg CTX eq/kg.

ratios indicate relative amounts as follows: CTX g- Ca M - PT mg

10

Example 10 Plasma concentration of ceftriaxone over time in rats
after intraduodenal (i.d.) administration of a ceftriaxone-
calcium-carrageenan complex

- 5 About 40 mg ceftriaxone (CTX) eq./kg of the complex described in
Example 1 was suspended in water and i.d. administered with 0.2
ml of capmul (an absorption enhancer) to four rats. At specific
time intervals, 0.6 ml of blood was taken from each rat and
centrifuged. About 0.2 ml of the blood plasma was then analyzed
10 for CTX by HPLC. The results are represented in
Table 7 below:

TABLE 7

Time After i.d. Dosage (minutes)	Average Plasma Concentration of CTX ($\mu\text{g/ml}$)
30	53
60	40
90	33
120	25
180	14
240	9

Example 11 - Plasma concentration of ceftriaxone over time in rats after intraduodenal (i.d.) administration of the CTX with capmul as control

As a control, about 40mg/kg of CTX was i.d. co-administered with 0.2 ml of capmul to four rats. See, *Chemotherapy* 34: 77-84 (1988). At specific time intervals, 0.6 ml of blood was taken from each rat and centrifuged. About 0.2 ml of the blood plasma was then analyzed for CTX by HPLC. The results are represented in Table 8 below:

10 TABLE 8

Time After i.d. Dosage (minutes)	Average Plasma Concentration of CTX (μ g/ml)
30	10
60	11
90	9
120	7
180	6
240	5

Example 12 - Plasma concentration of ceftriaxone over time in rats after i.v. administration

For comparison purposes, about 20mg/kg of CTX was administered (i.v.) to four rats. At specific time intervals, 0.6 ml of blood was taken from each rat and centrifuged. About 0.2 ml of the blood plasma was then analyzed for CTX by HPLC. The results are shown in Table 9 below:

TABLE 9

Study #	Test Article	Capmul: OCTX	Capmul: CTX	Capmul Conc. of Emulsion	Total Capmul Administered (g)	C max (µg/mL)	% Bioavailability
103-2	OCTX1 (C)		10:1	N/A		36 – 57	48.5
103-6	1 = OCTX1 (E) 2 = OCTX2 (C)	1 = 1:1 2 = 10:1	1 = 2.2:1 2 = 11:1	1 = 21.6 mg/mL 2 = N/A		1 = 5 – 7 2 = 44 – 55	3.3 44.6
103-7	1 = OCTX2 (E) 2 = OCTX2 (E)	1 = 5:1 2 = 10:1	1 = 9:1 2 = 18:1	1 = 97.8 mg/mL 2 = 179.4		1 = 43 – 49 2 = 19 – 39	47.9 23.6
103-8	CTX-Capmul (E)	5:1	6.25:1	62.5 mg/mL		14 - 30	14.6
103-9	CTX-CG	0	0	0		0	0
103-10	CTX-Capmul (E)		9:1			2.5 - 31	

(C) – Capmul chase

(E) – Capmul emulsion

Example 13 Preparation of meropenem-calcium-carageenan complex

Carrageenan was hydrated in water at a temperature of 50°C or higher. Next, an aqueous solution containing Ca²⁺ ions was prepared by dissolving calcium chloride in water.

Similarly, a meropenem solution was prepared by addition of meropenem to water. The meropenem solution and the calcium solution were then added simultaneously to the carrageenan solution. The meropenem-calcium-carrageenan solution was lyophilized.

Plasma concentration of meropenem over time in rats after intraduodenal administration of meropenem-calcium-carrageenan complex.

Meropenem was infused as a solution through an intraduodenal catheter followed by 0.2 ml. Capmul chase and a saline flush. The carrier formulation was meropenem in calcium- carrageenen to a final concentration of approximately 55% meropenem by weight. Two rats were dosed through a duodenum catheter and plasma samples were collected through 4 hours post dosage. For comparison purposes, a control group received meropenem reconstituted according to the manufacturers instructions, and infused as a solution through ID catheter followed by a saline flush.

Two fasted rats were dosed through a duodenal catheter and plasma samples were collected through 4 hours post dosage. These results show that meropenem was not absorbed and blood concentrations remained undetectable when prepared according to the art. A third rat expired

prior to dosage, possibly due to anesthesia required for surgery. Rat #1 expired at 4 hours, possibly due to the effects of prolonged anesthesia and blood collection.

Animal	C _{max} (@g/ml)	AUC _{0-4hr} (@gxhr/ml)	T _{1/2} (minutes)
Rat 1	5.98	5.54	35.2
Rat 2	2.83	1.44	19.7

5

Meropenem was rapidly absorbed and reached peak concentrations at the first time point (15 minutes) samples. IV dosage (in progress) will allow calculation of fraction absorbed (F%). AUC values of 1.4 and 5.4 @gxhr/ml suggest an oral F% of < 5%, assuming an IV dosage of 10 mg/kg would generate an AUC of > 30 @gxhr/ml..

The data show that meropenem was rapidly absorbed and reached peak concentrations at the first time point (15 minutes) samples. IV dosage will allow calculation of fraction absorbed. AUC values of 1.4 and 5.4 µg x hr/ml suggest an oral F% of < 5%, assuming an IV dosage of 10 mg/kg would generate an AUC of > 30 µgxhr/ml. Future trials will investigate absorption of naked meropenem and additional formulations.

Example 14: Daptomycin

About 400 mg of carrageenan was added to 80 ml of an aqueous solution containing 1.0 g (0.62 mmole) of Daptomycin.

The solution was then mixed by magnetic stirrer at room

5 temperature until the carrageenan was essentially fully swollen, forming a daptomycin-carrageenan hydrogel. Next, an aqueous solution containing calcium ions was prepared by dissolving 18.23 mg (0.125 mmole) of calcium chloride in 20 ml of water.

The entire aqueous solution was then dropped into the

10 daptomycin-carrageenan hydrogel or suspension. The complex was then mixed by a magnetic stirrer at room temperature for 2 hours. This resulted in the formation of a daptomycin-Ca-carrageenan gel complex. The daptomycin-Ca-carrageenan gel was then freeze-dried while in the swollen state. See Figure 2.

Results:

Time point	rat 1	rat 2	rat 3	rat 4
0	0.00	0.00	0.00	0.00
30	10.0	8.01	5.86	8.63
60	10.70	9.54	7.27	11.62
90	11.13	9.47	10.17	10.79
120	10.01	7.74	10.66	8.58
180	7.68	5.85	8.76	7.10
240	7.09	5.31	no sample	6.20

Example 15: PREPARATION OF AZTREONAM-Arg-CG

About 400 mg of carrageenan was added to 80 ml of an aqueous solution at approximately 50°C. The solution was then mixed by magnetic stirrer at room temperature until the carrageenan was essentially fully swollen. Next, an aqueous solution containing arginine was prepared by dissolving 240 mg (0.33 mole) of arginine in 10 ml of water. An aqueous solution of aztreonam was prepared by dissolving 120 mg aztreonam in 10ml of water. The entire volume of aztreonam and CaCl₂ solutions were simultaneously added dropwise to the hydrogel CG solution. The

dispersion was centrifuged and the supernatant removed for subsequent lyophilization to dryness. The resulting composition contains 7.57 mg of aztreonam/10 mg of composition, and can be milled to yield a fine powder.

5 Example 16: Preparation of Pipericillin-CG-CA

About 400 mg of carrageenan was added to 80 ml of an aqueous solution at approximately 50°C. The solution was then mixed by magnetic stirrer at room temperature until the carrageenan was essentially fully swollen. Next, an aqueous solution containing
10 Ca^{2+} ions was prepared by dissolving 54.5 mg (0.37 mmole) of calcium chloride in 10 ml of water. An aqueous solution of pipericillin was prepared by dissolving 1 mg (1.85 mmole) pipericillin in 10ml of water. The entire volume of pipericillin and CaCl_2 solutions were simultaneously added
15 dropwise to the hydrogel CG solution. The dispersion was centrifuged and the supernatant removed for subsequent lyophilization to dryness. 10 mg of the final composition contained 6.88 mg pipericillin.

Example 17: PREPARATION OF A VANCOMYCIN-CG-CA COMPLEX.

20 About 400 mg of carrageenan was added to 80 ml of an aqueous solution at approximately 50°C. The solution was then mixed by magnetic stirrer at room temperature until the

carrageenan was essentially fully swollen. Next, an aqueous solution containing Ca^{2+} ions was prepared by dissolving 20 mg (0.0.14mmole) of calcium chloride in 10 ml of water. An aqueous solution of vancomycin was prepared by dissolving 1 g (0.67 mmole) vancomycin in 10ml of water. The entire volume of vancomycin and CaCl_2 solutions were simultaneously added dropwise to the hydrogel CG solution. The dispersion was centrifuged and the supernatant removed for subsequent lyophilization to dryness. 10 mg of the resulting composition comprises 3.62 mg of vancomycin.

EXAMPLE 18: PREPARATION OF AN AMIKACIN-CG-CA COMPLEX

About 400 mg of carrageenan was added to 80 ml of an aqueous solution at approximately 50°C. The solution was then mixed by magnetic stirrer at room temperature until the carrageenan was essentially fully swollen. Next, an aqueous solution containing Ca^{2+} ions was prepared by dissolving 50 g of calcium chloride in 10 ml of water. An aqueous solution of amikacin was prepared by dissolving 1 g amikacin in 10ml of water. The entire volume of amikacin and CaCl_2 solutions were simultaneously added dropwise to the hydrogel CG solution. The dispersion was centrifuged and the supernatant removed for subsequent lyophilization to dryness. The resulting composition comprises 6.9 mg of amikacin/10 mg formulation.

Example 19: Preparation of amoxicillin-CG-CA

About 400 mg of carrageenan was added to 80 ml of an aqueous solution at approximately 50°C. The solution was then mixed by magnetic stirrer at room temperature until the carrageenan was essentially fully swollen. Next, an aqueous solution containing 5 Ca^{2+} ions was prepared by dissolving 69.98 mg (0.48 mmole) of calcium chloride in 10 ml of water. An aqueous solution of amoxicillin was prepared by dissolving .25 mg (0.6 mmole) amoxicillin in 10ml of water. The entire volume of amoxicillin and CaCl_2 solutions were simultaneously added dropwise to the 10 hydrogel CG solution. The dispersion was centrifuged and the supernatant removed for subsequent lyophilization to dryness. 10 mg of the final composition contained 3.47 mg amoxicillin.

While this invention has been particularly shown and described with references to a few preferred embodiments, it will be understood by those skilled in the art that various 25 changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

CLAIMS

What is claimed is:

1. A pharmaceutical composition for oral delivery of an antimicrobial agent comprising:
 - a) a biopolymer;
 - b) an antimicrobial agent entrained within or ionically bound to the biopolymer; and
 - c) a cationic binding agent entrained within or ionically bound to the biopolymer or the antimicrobial agent.
2. A pharmaceutical composition for oral delivery of an antimicrobial agent comprising:
 - a) a biopolymer;
 - b) an antimicrobial agent entrained within or ionically bound to the polymer;
 - c) a cationic binding agent entrained within or ionically bound to the biopolymer or the antimicrobial agent; and
 - d) an absorption enhancer.
3. The pharmaceutical composition of claim 1 or 2 wherein the biopolymer is selected from the group consisting of carrageenan, xylan, chitin, chitosan, chondroitin sulfate, sodium alginate, carboxymethylcellulose, pectin, polysaccharides, polypropylene glycols, polyethylene glycols,

polyacetates, liposomes, fatty acid complexes, cyclodextrins, cycloamyloses, clathrates, cycloalkyl amyloses, polyxylose, polylactic acids and combinations thereof.

4. The pharmaceutical composition of claim 1 or 2 wherein the antimicrobial agent is selected from the group consisting of cephalosporins, glycopeptides, penicillins, monobactams, oxazolidinones, lipopeptides, carbapenems, aminoglycosides, β -lactamase inhibitors and combinations thereof.
5. The pharmaceutical composition of claim 4 wherein the cephalosporin is selected from the group consisting of ceftiofur, cefipime, cefixime, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftizoxime, ceftriaxone, cefpirome, cefclidin, cefmenoxime, ceftazopran, and combinations thereof.
6. The pharmaceutical composition of claim 4 wherein the aminoglycoside is selected from the group consisting of amikacin, gentamicin, tobramycin, polymyxin-B, streptomycin, kanamycin and combinations thereof.
7. The pharmaceutical composition of claim 4 wherein the glycopeptide is selected from the group consisting of vancomycin, dalbavancin, oritavancin and combinations thereof.

8. The pharmaceutical composition of claim 4 wherein the carbapenem is selected from the group consisting of meropenem, imipenem, MK0826, R-115,685, J-114,870 and CP5068.
9. The pharmaceutical composition of claim 4 wherein the monobactam is aztreonam or carumonam.
10. The pharmaceutical composition of claim 4 wherein the penicillin is piperacillin or amoxicillin.
11. The pharmaceutical composition of claim 4 wherein the glycopeptide is vancomycin.
12. The pharmaceutical composition of claim 5 wherein the cephalosporin is ceftriaxone.
13. The pharmaceutical composition of claim 4 wherein the lipopeptide is daptomycin.
14. The pharmaceutical composition of claim 1 or 2 wherein the cationic binding agent is selected from the group consisting of calcium, magnesium, lithium, iron, copper, zinc, aluminum, manganese, chromium, cobalt, nickel, ammonium salts and combinations thereof.
15. The pharmaceutical composition of claim 12 wherein the cationic binding agent is calcium.
16. The pharmaceutical composition of claim 12 wherein the cationic binding agent is zinc.

17. The pharmaceutical composition of claim 1 or 2 wherein the cationic binding agent is ionically bound to the biopolymer forming a cationic binding agent-biopolymer complex and the antimicrobial agent is contained within the cationic binding agent-biopolymer complex.
18. The pharmaceutical composition of claim 1 or 2 wherein the cationic binding agent is ionically bound to the antimicrobial agent forming a cationic binding agent-antimicrobial complex and the cationic binding agent-antimicrobial complex is contained within the biopolymer.
19. The pharmaceutical composition of claim 1 or 2 wherein the cationic binding agent is complexed to the antimicrobial and the cationic binding agent is further ionically bound to the biopolymer forming an antimicrobial-cationic binding agent-biopolymer bridge.
20. The pharmaceutical composition of claim 1 or 2 wherein the biopolymer is carrageenan or pectin.
21. The pharmaceutical composition of claim 17 wherein the carrageenan has a calcium content of less than about 0.4% by weight.
22. The pharmaceutical composition of claim 2 wherein the biopolymer is carrageenan, the antimicrobial agent is

ceftriaxone, the metal cation is calcium and the absorption enhancer is capmul.

23. The pharmaceutical composition of claim 1 or 2 wherein the cationic binding agent is selected from the group consisting of cationic polymers, metal cations, basic amino acids, quaternary ammonium salts, and combinations thereof.
24. The pharmaceutical composition of claim 21 wherein the cationic binding agent is a cationic polymer.
25. The pharmaceutical composition of claim 21 wherein the cationic binding agent is a basic amino acid.
26. The pharmaceutical composition of claim 21 wherein the cationic binding agent is a quaternary ammonium salt.
27. The pharmaceutical composition of claim 21 wherein the cationic polymer selected from the group consisting of poly(allylamine), poly-(L-lysine), poly-(L-arginine), dodecyl trimethyl ammonium bromide, polyethylenimines (primary, secondary, and tertiary), and combinations thereof.
28. The pharmaceutical composition of claim 21 wherein the basic amino acid is selected from the group consisting of arginine, lysine, histidine, and combinations thereof.
29. The pharmaceutical composition of claim 21 wherein the quaternary ammonium salt is selected from the group

- consisting of benzalkonium derivatives, cetyl pyridinium derivatives, dodecyl-trimethyl ammonium salt derivatives, tetradecyl-trimethyl ammonium salt derivatives, cetyl-trimethyl ammonium salt derivatives, and combinations thereof.
30. The pharmaceutical composition of claim 25 wherein the biopolymer is carrageenan, the antimicrobial is ceftriaxone, and the cationic molecule is arginine.
31. The pharmaceutical composition of claim 25 wherein the biopolymer is carrageenan, the antimicrobial is ceftriaxone, and the cationic molecule is lysine.
32. The pharmaceutical composition of claim 1 or 2 wherein the biopolymer is carrageenan, the antimicrobial is ceftriaxone, and the cationic binding agent is cetyl pyridinium chloride.
33. The pharmaceutical composition of claim 2 wherein the biopolymer is carrageenan, the antimicrobial agent is daptomycin and the cationic binding agent is calcium.
34. The pharmaceutical composition of claim 1 further comprising an absorption enhancer.
35. The pharmaceutical composition of claim 32 wherein the absorption enhancer is selected from the group consisting of a monoglyceride of a C₁₂-C₁₈ fatty acid, a diglyceride of

- a C₆-C₁₈ fatty acid, a triglyceride of a C₁₂-C₁₈ fatty acid, gelucire and mixtures thereof.
36. An enterically coated tablet or capsule comprising the pharmaceutical composition of claim 1 or 2.
37. A suspension comprising enterically coated particles wherein the particles comprise the pharmaceutical composition of claim 2.
38. The composition of claim 2 wherein the absorption enhancing agent is an agent selected from the group consisting of lipids, gelucire, capric and caprylic acids, oleic acids, palmitic acids, stearic acids and Capmuls.
39. A method for treating an animal comprising administering to an animal in need thereof a pharmaceutical composition comprising a biopolymer, an antimicrobial agent entrained within or ionically bound to the biopolymer, and a cationic binding agent entrained within or ionically bound to the biopolymer or the antimicrobial agent.
40. The method of claim 40 wherein the pharmaceutical composition further comprises an absorption enhancing agent.
41. The method of claim 39 further comprising administering to said animal an absorption enhancing agent.

FIGURE 1

Intraduodenal Dosing in Monkeys
20 mg/kg OCTX1 + Capmul




FIGURE 2

Oral Daptomycin pK Study





FIGURE 3

NEAD-103

Session 7: OCTX-2 (CTX:Capmul, 1:9)

Session 9: OCTX-2 (No Capmul)

Session 10: CTX (CTX:Capmul, 1:9)




—○— Session 7 (Monkey's 1001, 1002)
—○— Session 9 (Monkey's 1001, 1002, 1003 & 1004)
—▽— Session 10 (Monkey's 1001, 1002, 1003 & 1004)

FIGURE 4

Intraduodenal Dosing in Rats

40 mg/kg OCTX1 + Capmul



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97851 A3

(51) International Patent Classification⁷: A61K 9/16, 47/36

60008 (US). UNIVERSITY OF UTAH RESEARCH FOUNDATION [US/US]: 615 Arapsee Drive, Salt Lake City, UT 84108 (US).

(21) International Application Number: PCT/US01/19625

(22) International Filing Date: 18 June 2001 (18.06.2001)

(72) Inventors; and

(25) Filing Language: English

(75) Inventors/Applicants (for US only): CHOI, Seung-Ho [KR/US]: 3156 Kuibab Way, Salt Lake City, UT 84109 (US). LEE, Jeoung-Soo [KR/US]: 5322 South Cobble Creek Road #16B, Salt Lake City, UT 84117 (US). KEITH, Dennis [US/US]: 64 Lake Street, Arlington, MA 02474 (US).

(26) Publication Language: English

(30) Priority Data:

09/598,089	21 June 2000 (21.06.2000)	US
09/829,405	9 April 2001 (09.04.2001)	US
60/283,976	16 April 2001 (16.04.2001)	US

(74) Agents: MYERS, Louis et al.: Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).

(71) Applicants (for all designated States except US): CUBIST PHARMACEUTICALS, INC. [US/US]: 24 Emily Street, Cambridge, MA 02139 (US). INTERNATIONAL HEALTH MANAGEMENT ASSOCIATES, INC. [US/US]: 1675 Winnetka Circle, Rolling Meadows, IL

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,

[Continued on next page]


(54) Title: COMPOSITIONS AND METHODS TO IMPROVE THE ORAL ABSORPTION OF ANTIMICROBIAL AGENTS

NEAD-103

Session 7: OCTX-2 (CTX:Capmul, 1:9)

Session 9: OCTX-2 (No Capmul)

Session 10: CTX (CTX:Capmul, 1:9)



(57) Abstract: The present invention provides compositions and methods for increasing absorption of antibacterial agents, particularly third generation cephalosporin antibacterial agents, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, an antimicrobial agent, and a cationic binding agent contained within the biopolymer such that the binding agent is ionically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent.

—○— Session 7 (Monkey's 1001, 1002)
—□— Session 9 (Monkey's 1001, 1002, 1003 & 1004)
—△— Session 10 (Monkey's 1001, 1002, 1003 & 1004)

WO 01/97851 A3



SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) **Date of publication of the international search report:**

16 May 2002

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/19625

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/16 A61K47/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 526 862 A (VECTORPHARMA INTERNATIONAL S.P.A., IT) 10 February 1993 (1993-02-10) claims 1,7,9,10,15,16,18-22 page 6, line 34 - line 37 ---	1,3-5, 10,12, 14,20, 23,36, 37,39
A	EP 0 580 428 A (TAKEDA) 26 January 1994 (1994-01-26) claims 1,2,7,11,15,18,21-23,26,35,39,42,46 example 6 ---	1-41
A	US 4 188 373 A (J. Z. KREZANOSKI) 12 February 1980 (1980-02-12) claims ---	1-41
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

28 February 2002

Date of mailing of the international search report

14/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

Inter. onal Application No

PCT/US 01/19625

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 207 624 A (COLUMBIA UNIVERSITY) 7 January 1987 (1987-01-07) claims page 6, line 1 - line 4 page 6, line 14 - line 17 page 6, line 28 ---	1-41
A	DATABASE WPI Section Ch, Week 198522 Derwent Publications Ltd., London, GB; Class B02, AN 1985-130919 XP002191570 & JP 60 067413 A (KYOTO YAKUHI KOGYO KK), 17 April 1985 (1985-04-17) abstract -----	1-41

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/19625

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 526862	A	10-02-1993	IT 1251153 B AT 134134 T DE 69208299 D1 DE 69208299 T2 EP 0526862 A1 ES 2086029 T3	04-05-1995 15-02-1996 28-03-1996 18-07-1996 10-02-1993 16-06-1996
EP 580428	A	26-01-1994	AT 158718 T AU 4198793 A CA 2101183 A1 CN 1088092 A DE 69314253 D1 DE 69314253 T2 EP 0580428 A1 HU 67277 A2 JP 6293636 A US 5723269 A	15-10-1997 27-01-1994 25-01-1994 22-06-1994 06-11-1997 29-01-1998 26-01-1994 28-03-1995 21-10-1994 03-03-1998
US 4188373	A	12-02-1980	US 4100271 A AU 515420 B2 AU 2794977 A CA 1090252 A1 CH 629385 A5 DE 2708152 A1 FR 2400903 A1 GB 1571832 A JP 1157132 C JP 52125619 A JP 57048049 B NL 7709273 A	11-07-1978 02-04-1981 22-02-1979 25-11-1980 30-04-1982 08-09-1977 23-03-1979 23-07-1980 15-07-1983 21-10-1977 14-10-1982 27-02-1979
EP 207624	A	07-01-1987	US 4612337 A AU 586863 B2 AU 5808686 A CA 1268118 A1 DE 3677835 D1 EP 0207624 A2 IE 58945 B JP 1629398 C JP 2056103 B JP 62011457 A MX 165855 B	16-09-1986 27-07-1989 04-12-1986 24-04-1990 11-04-1991 07-01-1987 01-12-1993 20-12-1991 29-11-1990 20-01-1987 08-12-1992
JP 60067413	A	17-04-1985	NONE	